Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment

Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies

Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526

Neurotoxic reactive astrocytes are induced by activated microglia

Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971

Neuroinflammation in Alzheimer's disease

Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226

The Nuclear Factor NF- B Pathway in InflammationPreprint

Lawrence, T. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001651 · Cited by 5,126

An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex

Zhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O'Keeffe, S., Phatnani, H. P., Guarnieri, P., Caneda, C., Ruderisch, N., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1860-14.2014 · Cited by 4,875

A Meta-Analysis of Cytokines in Major Depression

Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729

Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?

Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179

Reactive astrocyte nomenclature, definitions, and future directions

Escartin, C., Galea, E., Lakatos, A., O’Callaghan, J. P., Petzold, G. C., Serrano-Pozo, A., Steinhäuser, C., Volterra, A., Carmignoto, G., Agarwal, A., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00783-4 · Cited by 2,513

New insights into the genetic etiology of Alzheimer’s disease and related dementias

Bellenguez, C., Küçükali, F., Jansen, I. E., Kleineidam, L., Moreno-Grau, S., Amin, N., Naj, A. C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01024-z · Cited by 2,498

Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse

Zhang, Y., Sloan, S. A., Clarke, L. E., Caneda, C., Plaza, C. A., Blumenthal, P. D., Vogel, H., Steinberg, G. K., Edwards, M. S. B., Li, G., et al. (2016) · Neuron · doi:10.1016/j.neuron.2015.11.013 · Cited by 2,295

Complex cell-state changes revealed by single cell RNA sequencing of 76,149 microglia throughout the mouse lifespan and in the injured brain

Hammond, T. R., Dufort, C., Dissing-Olesen, L., Giera, S., Young, A., Wysoker, A., Walker, A. J., Segel, M., Nemesh, J., Saunders, A., et al. (2018) · doi:10.1101/406140 · Cited by 2,225

Neuroinflammation in Parkinson’s disease: A target for neuroprotection?

Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984

Glucagon-like peptide-1 7–36: a physiological incretin in man

Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928

Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline

Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651

Neuroinflammation: The Devil Is in the Details

DiSabato, D. J., Quan, N., & Godbout, J. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13607 · Cited by 1,640

Pericytes Control Key Neurovascular Functions and Neuronal Phenotype in the Adult Brain and during Brain Aging

Bell, R. D., Winkler, E. A., Sagare, A. P., Singh, I., LaRue, B., Deane, R., & Zlokovic, B. V. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.043 · Cited by 1,448

Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease

Wang, X., Wang, W., Li, L., Perry, G., Lee, H.-G., & Zhu, X. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.10.015 · Cited by 1,357

Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice

Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311

Reduced incretin effect in Type 2 (non-insulin dependent) diabetes

Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307

Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease

Kisler, K., Nelson, A. R., Montagne, A., & Zlokovic, B. V. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.48 · Cited by 1,243

Normal aging induces A1-like astrocyte reactivity

Clarke, L. E., Liddelow, S. A., Chakraborty, C., Münch, A. E., Heiman, M., & Barres, B. A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1800165115 · Cited by 1,237

Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease

Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.

Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000

Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the Migrating Front of Human Glioblastoma

Darmanis, S., Sloan, S. A., Croote, D., Mignardi, M., Chernikova, S. B., Samghababi, P., Zhang, Y., Neff, N. F., Kowarsky, M., Caneda, C., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.030 · Cited by 991

Astrocytes: Key Regulators of Neuroinflammation

Colombo, E., & Farina, C. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.06.006 · Cited by 936

NF-kappaB Signaling Pathways in Neurological Inflammation: A Mini Review

Shih, R., Wang, C.-Y., & Yang, C. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00077 · Cited by 935

Insulin resistance: review of the underlying molecular mechanisms

Yaribeygi, H., Farrokhi, F. R., Butler, A. E., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27603 · Cited by 929

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889

STIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1

Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers

Bomfim, T. R., Forny‐Germano, L., Sathler, L. B., Brito‐Moreira, J., Houzel, J., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57256 · Cited by 849

Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease

Rocha, E. M., Miranda, B. D., & Sanders, L. H. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.04.004 · Cited by 801

Neuroinflammation: The role and consequences

Lyman, M., Lloyd, D. G., Ji, X., Vizcaychipi, M. P., & Ma, D. (2013) · Neuroscience Research · doi:10.1016/j.neures.2013.10.004 · Cited by 776

Semaglutide lowers body weight in rodents via distributed neural pathways.

Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696

Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes

Nortley, R., Korte, N., Izquierdo, P., Hirunpattarasilp, C., Mishra, A., Jaunmuktane, Z., Kyrargyri, V., Pfeiffer, T., Khennouf, L., Madry, C., et al. (2019) · Science · doi:10.1126/science.aav9518 · Cited by 682

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease

Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680

The Cardiovascular Biology of Glucagon-like Peptide-1

Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665

Neuroinflammation pathways: a general review

Shabab, T., Khanabdali, R., Moghadamtousi, S. Z., Kadir, H. A., & Mohan, G. (2016) · International Journal of Neuroscience · doi:10.1080/00207454.2016.1212854 · Cited by 657

What is a pericyte?

Attwell, D., Mishra, A., Hall, C. N., O’Farrell, F. M., & Dalkara, T. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x15610340 · Cited by 648

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641

Dynamic changes in local cerebral glucose utilization following cerebral concussion in rats: evidence of a hyper- and subsequent hypometabolic state

Yoshino, A., Hovda, D. A., Kawamata, T., Katayama, Y., & Becker, D. P. (1991) · Brain Research · doi:10.1016/0006-8993(91)90755-k · Cited by 592

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589

Neurotoxic reactive astrocytes induce cell death via saturated lipids

Guttenplan, K. A., Weigel, M. K., Prakash, P., Wijewardhane, P. R., Hasel, P., Rufen-Blanchette, U., Münch, A. E., Blum, J. A., Fine, J., Neal, M. C., et al. (2021) · Nature · doi:10.1038/s41586-021-03960-y · Cited by 578

Exenatide and the treatment of patients with Parkinson's disease

Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529

Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease

Paradies, G. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14205 · Cited by 525

Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetes

Takeda, S., Sato, N., Uchio‐Yamada, K., Sawada, K., Kunieda, T., Takeuchi, D., Kurinami, H., Shinohara, M., Rakugi, H., & Morishita, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000645107 · Cited by 515

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504

A transcriptomic atlas of aged human microglia

Olah, M., Patrick, E., Villani, A.-C., Xu, J., White, C. C., Ryan, K. J., Piehowski, P., Kapasi, A., Nejad, P., Cimpean, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02926-5 · Cited by 482

Mitochondrial dysfunction and mitophagy in parkinson’s disease: from mechanism to therapy

Malpartida, A. B., Williamson, M., Narendra, D. P., Wade-Martins, R., & Ryan, B. J. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.11.007 · Cited by 482

Interactions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier

Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480

In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial

Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480

Neuroinflammatory processes in Alzheimer’s disease

Heneka, M. T., O’Banion, M. K., Terwel, D., & Kummer, M. P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0438-z · Cited by 433

Transcription Factor NF‐κB: A Sensor for Smoke and Stress Signals

Ahn, K., & Aggarwal, B. B. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1352.026 · Cited by 431

Effect of Truncated Glucagon-Like Peptide-1 [Proglucagon-(78–107) amide] on Endocrine Secretion from Pig Pancreas, Antrum, and Nonantral Stomach

Ørskov, C., Holst, J. J., & Nielsen, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396

Epac: A New cAMP-Binding Protein in Support of Glucagon-Like Peptide-1 Receptor-Mediated Signal Transduction in the Pancreatic β-Cell

Holz, G. G. (2004) · Diabetes · doi:10.2337/diabetes.53.1.5 · Cited by 392

Pericyte loss leads to circulatory failure and pleiotrophin depletion causing neuron loss

Nikolakopoulou, A. M., Montagne, A., Kisler, K., Dai, Z., Wang, Y., Huuskonen, M. T., Sagare, A. P., Lazić, D., Sweeney, M. D., Kong, P., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0434-z · Cited by 386

Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4

Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037481 · Cited by 380

Impact of Metabolic Syndrome on Neuroinflammation and the Blood–Brain Barrier

Dyken, P. C. V., & Lacoste, B. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00930 · Cited by 377

Functions and dysfunctions of nitric oxide in brain

Picón-Pagès, P., Garcia-Buendia, J., & Muñoz, F. J. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.11.007 · Cited by 369

IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures

Vezzani, A., Maroso, M., Balosso, S., Sanchez, M.-A., & Bartfai, T. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.03.018 · Cited by 362

Entry of exendin-4 into brain is rapid but may be limited at high doses

Kastin, A. J., & Akerstrom, V. L. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802206 · Cited by 358

Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse

Campos, R. V., Lee, Y. C., & Drucker, D. J. (1994) · Endocrinology · doi:10.1210/endo.134.5.8156917 · Cited by 353

Glucagon‐like peptide‐1 decreases endogenous amyloid‐β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron

Perry, T., Lahiri, D. K., Sambamurti, K., Chen, D., Mattson, M. P., Egan, J. M., & Greig, N. H. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10611 · Cited by 347

The cAMP signalling pathway activates CREB through PKA, p38 and MSK1 in NIH 3T3 cells

Delghandi, M. P., Johannessen, M., & Moens, U. L. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2005.02.003 · Cited by 334

Insulin gene expression and insulin synthesis in mammalian neuronal cells.

Devaskar, S. U., Giddings, S. J., Rajakumar, P. A., Carnaghi, L. R., Menon, R. K., & Zahm, D. S. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37214-9 · Cited by 333

Inflammatory Cytokines in Acute Ischemic Stroke

Tuttolomondo, A., Di Raimondo, D., di Sciacca, R., Pinto, A., & Licata, G. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208786848739 · Cited by 325

Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake

Adriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324

GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease

Li, Y., Duffy, K. B., Ottinger, M. A., Ray, B., Bailey, J. A., Holloway, H. W., Tweedie, D., Perry, T., Mattson, M. P., Kapogiannis, D., et al. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1314 · Cited by 323

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes

Frias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321

Type 2 Diabetes as a Risk Factor for Alzheimer's Disease: The Confounders, Interactions, and Neuropathology Associated With This Relationship

Vagelatos, N. T., & Eslick, G. D. (2013) · Epidemiologic Reviews · doi:10.1093/epirev/mxs012 · Cited by 320

The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials

Min, T., & Bain, S. C. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00981-0 · Cited by 314

The expression of GLP‐1 receptor mRNA and protein allows the effect of GLP‐1 on glucose metabolism in the human hypothalamus and brainstem

Álvarez, E., Martínez, M. D., Roncero, I., Chowen, J. A., Cuartero, B. G., Gispert, J. D., Sanz, C., Vázquez, P., Maldonado, A., Cáceres, J. D., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02914.x · Cited by 307

A Novel Neurotrophic Property of Glucagon-Like Peptide 1: A Promoter of Nerve Growth Factor-Mediated Differentiation in PC12 Cells

Perry, T., Lahiri, D. K., Chen, D., Zhou, J., Shaw, K. T. Y., Egan, J. M., & Greig, N. H. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.958 · Cited by 303

Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function

Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302

Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease

Avilés-Olmos, I., Dickson, J. C., Kefalopoulou, Z. M., Djamshidian, A., Kahan, J., Ell, P. J., Whitton, P. S., Wyse, R. K. H., Isaacs, T., Lees, A. J., et al. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-140364 · Cited by 300

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study

Ambery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298

The role of glucose transporters in brain disease: Diabetes and Alzheimer’s disease

Shah, K., DeSilva, S., & Abbruscato, T. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012629 · Cited by 288

VDAC1, mitochondrial dysfunction, and Alzheimer’s disease

Shoshan-Barmatz, V., Nahon-Crystal, E., Shteinfer-Kuzmine, A., & Gupta, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.010 · Cited by 286

Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease

Abbas, T. F., Faivre, É., & Hölscher, C. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.06.035 · Cited by 285

Vascular Dysfunction in Alzheimer’s Disease: A Prelude to the Pathological Process or a Consequence of It?

Govindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 281

Neuroinflammation in mild cognitive impairment and Alzheimer’s disease: A meta-analysis

Bradburn, S., Murgatroyd, C., & Ray, N. J. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.01.002 · Cited by 277

Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia

Krieger, J.-P., Arnold, M., Pettersen, K. G., Lossel, P., Langhans, W., & Lee, S. J. (2016) · Diabetes · doi:10.2337/db15-0973 · Cited by 269

Peptides and the blood–brain barrier

Banks, W. A. (2015) · Peptides · doi:10.1016/j.peptides.2015.03.010 · Cited by 267

Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease

Athauda, D. S., Gulyani, S., Karnati, H. K., Li, Y., Tweedie, D., Mustapić, M., Chawla, S., Chowdhury, K., Skene, S. S., Greig, N. H., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4304 · Cited by 259

Multiple system atrophy

Fanciulli, A., Stanković, I., Krismer, F., Seppi, K., Levin, J., & Wenning, G. K. (2019) · International review of neurobiology · doi:10.1016/bs.irn.2019.10.004 · Cited by 259

Interleukin-1β-Induced Changes in Blood–Brain Barrier Permeability, Apparent Diffusion Coefficient, and Cerebral Blood Volume in the Rat Brain: A Magnetic Resonance Study

Blamire, A. M., Anthony, D. C., Rajagopalan, B., Sibson, N. R., Perry, V. H., & Styles, P. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-21-08153.2000 · Cited by 249

The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review

Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248

Targeting pericytes for therapeutic approaches to neurological disorders

Cheng, J., Korte, N., Nortley, R., Sethi, H., Tang, Y., & Attwell, D. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1893-0 · Cited by 247

Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease

Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., & Hölscher, C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.054 · Cited by 246

Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight

Baggio, L. L., & Drucker, D. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci78371 · Cited by 245

Neuroinflammation and microglia in glaucoma: time for a paradigm shift

Wei, X., Cho, K., Thee, E. F., Jager, M. J., & Chen, D. F. (2018) · Journal of Neuroscience Research · doi:10.1002/jnr.24256 · Cited by 239

Insulin Resistance in Alzheimer's Disease

Ferreira, L. S. S., Fernandes, C., Vieira, M. N. N., & Felice, F. G. D. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00830 · Cited by 238

Unimolecular Polypharmacy for Treatment of Diabetes and Obesity

Tschöp, M. H., Finan, B., Clemmensen, C., Gelfanov, V. M., Pérez–Tilve, D., Müller, T. D., & DiMarchi, R. D. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.021 · Cited by 236

Cellular senescence at the crossroads of inflammation and Alzheimer's disease

Guerrero, A., De Strooper, B., & Arancibia-Cárcamo, I. L. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2021.06.007 · Cited by 236

Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes

Brauer, R., Wei, L., Ma, T., Athauda, D., Girges, C., Vijiaratnam, N., Auld, G., Whittlesea, C., Wong, I., & Foltynie, T. (2020) · Brain · doi:10.1093/brain/awaa262 · Cited by 233

Identification of early pericyte loss and vascular amyloidosis in Alzheimer’s disease retina

Shi, H., Koronyo, Y., Rentsendorj, A., Regis, G. C., Sheyn, J., Fuchs, D.-T., Kramerov, A. A., Ljubimov, A. V., Dumitrascu, O. M., Rodriguez, A. R., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02134-w · Cited by 230

RTP801 Is Induced in Parkinson's Disease and Mediates Neuron Death by Inhibiting Akt Phosphorylation/Activation

Malagelada, C., Jin, Z. H., & Greene, L. A. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3928-08.2008 · Cited by 228

Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer’s Disease

Mullins, R. J., Diehl, T. C., Chia, C. W., & Kapogiannis, D. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00118 · Cited by 227

Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis

Lecca, D., Jung, Y. J., Scerba, M. T., Hwang, I., Kim, Y. K., Kim, S., Modrow, S., Tweedie, D., Hsueh, S., Liu, D., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12610 · Cited by 225

Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides

Hupe-Sodmann, K., McGregor, G. P., Bridenbaugh, R., Göke, R., Göke, B., Thole, H., Zimmermann, B., & Voigt, K. (1995) · Regulatory Peptides · doi:10.1016/0167-0115(95)00063-h · Cited by 224

Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development

Robichaux, W. G., & Cheng, X. (2018) · Physiological Reviews · doi:10.1152/physrev.00025.2017 · Cited by 222

Inflammatory Process in Alzheimer's and Parkinson's Diseases: Central Role of Cytokines

Alam, Q., Alam, M. Z., Mushtaq, G., Damanhouri, G. A., Rasool, M., Kamal, M. A., & Haque, A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151125000300 · Cited by 220

Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)

Femminella, G. D., Frangou, E., Love, S., Busza, G., Holmes, C., Ritchie, C. W., Lawrence, R., McFarlane, B., Tadros, G., Ridha, B. H., et al. (2019) · Trials · doi:10.1186/s13063-019-3259-x · Cited by 220

Single-Cell Analysis of Blood-Brain Barrier Response to Pericyte Loss

Mäe, M. A., He, L., Nordling, S., Vázquez-Liébanas, E., Nahar, K., Jung, B., Li, X., Tan, B. C., Foo, J. C., Cazenave‐Gassiot, A., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.317473 · Cited by 220

Pro-inflammatory cytokines and their effects in the dentate gyrus

Pickering, M., & O’Connor, J. J. (2007) · Progress in Brain Research · doi:10.1016/s0079-6123(07)63020-9 · Cited by 217

Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer’s disease and tauopathies

Yarchoan, M. M., Toledo, J. B., Lee, E. B., Arvanitakis, Z., Kazi, H., Han, L.-Y., Louneva, N., Lee, V. M. ‐., Kim, S. F., Trojanowski, J. Q., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1328-5 · Cited by 215

Neuroinflammation and Cognitive Aging

Ownby, R. L. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-009-0082-1 · Cited by 212

Amelioration of Acute Sequelae of Blast Induced Mild Traumatic Brain Injury by N-Acetyl Cysteine: A Double-Blind, Placebo Controlled Study

Hoffer, M. E., Balaban, C., Slade, M. D., Tsao, J. W., & Hoffer, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054163 · Cited by 207

Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models

Hölscher, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.040 · Cited by 203

Akt signal transduction dysfunction in Parkinson's disease

Timmons, S., Coakley, M. F., Moloney, A. M., & Neill, C. O. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.09.055 · Cited by 192

Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer’s disease

Park, J.-S., Kam, T.-I., Lee, S., Park, H., Oh, Y., Kwon, S.-H., Song, J.-J., Kim, D., Kim, H., Jhaldiyal, A., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01180-z · Cited by 192

Glucose-Dependent Insulinotropic Polypeptide Is Expressed in Adult Hippocampus and Induces Progenitor Cell Proliferation

Nyberg, J., Anderson, M. F., Meister, B., Alborn, A.-M., Ström, A.-K., Brederlau, A., Illerskog, A.-C., Nilsson, O., Kieffer, T. J., Hietala, M. A., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4920-04.2005 · Cited by 191

Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease

Troncoso-Escudero, P., Parra, A., Nassif, M., & Vidal, R. L. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00860 · Cited by 191

The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke

Shan, Y., Tan, S., Lin, Y., Liao, S., Zhang, B., Chen, X., Wang, J., Deng, Z., Zeng, Q., Zhang, L., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1638-6 · Cited by 191

Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer’s and Parkinson’s disease therapeutics

Salameh, T. S., Rhea, E. M., Talbot, K., & Banks, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114187 · Cited by 188

Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans

Asmar, M., Simonsen, L., Madsbad, S., Stallknecht, B., Holst, J. J., & Bülow, J. (2010) · Diabetes · doi:10.2337/db10-0098 · Cited by 184

Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease

Dionisio-Santos, D. A., Olschowka, J. A., & O’Banion, M. K. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1453-0 · Cited by 184

Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy

Perry, T., Holloway, H. W., Weerasuriya, A., Mouton, P. R., Duffy, K. B., Mattison, J. A., & Greig, N. H. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.09.028 · Cited by 183

Brain insulin resistance: role in neurodegenerative disease and potential for targeting

Hölscher, C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1738383 · Cited by 180

Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist

Bossart, M., Wagner, M., Elvert, R., Evers, A., Hübschle, T., Kloeckener, T., Lorenz, K., Moessinger, C., Eriksson, O., Velikyan, I., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.005 · Cited by 179

Hippocampal GLP-1 Receptors Influence Food Intake, Meal Size, and Effort-Based Responding for Food through Volume Transmission

Hsu, T. M., Hahn, J. D., Konanur, V. R., Lam, A., & Kanoski, S. E. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.175 · Cited by 176

Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectives

Seino, Y., Kuwata, H., & Yabe, D. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12490 · Cited by 174

Review: Traumatic brain injury and hyperglycemia, a potentially modifiable risk factor

Shi, J., Dong, B., Mao, Y., Guan, W., Cao, J., Zhu, R., & Wang, S. (2016) · Oncotarget · doi:10.18632/oncotarget.11958 · Cited by 174

Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease

McClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.015 · Cited by 170

A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus

Botfield, H. F., Uldall, M., Westgate, C. S. J., Mitchell, J., Hagen, S. M., Gonzalez, A. M., Hodson, D. J., Jensen, R., & Sinclair, A. J. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0972 · Cited by 168

Midlife adiposity and the future risk of Parkinson’s disease

Abbott, R. D., Ross, G. W., White, L. R., Nelson, J. S., Masaki, K., Tanner, C. M., Curb, J. D., Blanchette, P. L., Popper, J. S., & Petrovitch, H. (2002) · Neurology · doi:10.1212/wnl.59.7.1051 · Cited by 163

Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment

Gejl, M., Brock, B., Egefjord, L., Vang, K., Rungby, J., & Gjedde, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-17718-y · Cited by 163

A Pilot Study of Exenatide Actions in Alzheimer’s Disease

Mullins, R. J., Mustapić, M., Chia, C. W., Carlson, O. D., Gulyani, S., Tran, J., Li, Y., Mattson, M. P., Resnick, S. M., Egan, J. M., et al. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190913155950 · Cited by 162

Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease

Hölscher, C. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390891 · Cited by 158

Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes

Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice

Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152

Adipose oxidative stress and protein carbonylation

Hauck, A. K., Huang, Y., Hertzel, A. V., & Bernlohr, D. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.r118.003214 · Cited by 152

Enhancing the GLP‐1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells

Li, Y., Tweedie, D., Mattson, M. P., Holloway, H. W., & Greig, N. H. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06731.x · Cited by 150

Metabolic syndrome and risk of Parkinson disease: A nationwide cohort study

Nam, G. E., Kim, S. M., Han, K., Kim, N. H., Chung, H. S., Kim, J. W., Han, B., Cho, S.-J., Yu, J. H., Park, Y. G., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002640 · Cited by 148

If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?

Haass, C., & Selkoe, D. (2022) · PLOS Biology · doi:10.1371/journal.pbio.3001694 · Cited by 145

Brain Uptake of the Glucagon-Like Peptide-1 Antagonist Exendin(9-39) after Intranasal Administration

Banks, W. A., During, M. J., & Niehoff, M. L. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.063222 · Cited by 144

The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects

Hui, H., Farilla, L., Merkel, P. A., & Perfetti, R. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460863 · Cited by 144

Diabetes drugs in the fight against Alzheimer's disease

Boccardi, V., Murasecco, I., & Mecocci, P. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100936 · Cited by 142

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

Kishimoto, M. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s35682 · Cited by 139

A New Treatment Strategy for Parkinson's Disease through the Gut–Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway

Kim, D. S., Choi, H.-I., Wang, Y., Luo, Y., Hoffer, B. J., & Greig, N. H. (2017) · Cell Transplantation · doi:10.1177/0963689717721234 · Cited by 136

Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease

Tai, J., Liu, W., Li, Y., Li, L., & Hölscher, C. (2017) · Brain Research · doi:10.1016/j.brainres.2017.10.012 · Cited by 135

Insulin resistance and clinical outcomes after acute ischemic stroke

Ago, T., Matsuo, R., Hata, J., Wakisaka, Y., Kuroda, J., Kitazono, T., Kamouchi, M., & On behalf of the Fukuoka Stroke Registry Investigators (2018) · Neurology · doi:10.1212/wnl.0000000000005358 · Cited by 135

Adult murine hippocampal neurogenesis is inhibited by sustained IL-1β and not rescued by voluntary running

Wu, M. D., Hein, A. M., Moravan, M. J., Shaftel, S. S., Olschowka, J. A., & O’Banion, M. K. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.09.012 · Cited by 134

Neural correlates of liraglutide effects in persons at risk for Alzheimer’s disease

Watson, K. T., Wroolie, T., Tong, G., Foland‐Ross, L. C., Frangou, S., Singh, M. K., McIntyre, R. S., Roat-Shumway, S., Myoraku, A., Reiss, A. L., et al. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.08.006 · Cited by 134

Astrocytes Regulate GLP-1 Receptor-Mediated Effects on Energy Balance

Reiner, D. J., Mietlicki-Baase, E. G., McGrath, L. E., Zimmer, D. J., Bence, K. K., Sousa, G. L., Konanur, V. R., Krawczyk, J., Burk, D. H., Kanoski, S. E., et al. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3579-15.2016 · Cited by 133

Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis

Li, Y., Chigurupati, S., Holloway, H. W., Mughal, M. R., Tweedie, D., Bruestle, D. A., Mattson, M. P., Wang, Y., Harvey, B. K., Ray, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032008 · Cited by 131

Insulin receptor mRNA in the substantia nigra in Parkinson's disease.

Takahashi, M., Yamada, T., Tooyama, I., Moroo, I., Kimura, H., Yamamoto, T., & Okada, H. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12357-0 · Cited by 131

Effect of porcine gastric inhibitory polypeptide on β-cell function in type I and type II diabetes mellitus

Krarup, T., Saurbrey, N., Moody, A. J., Kühl, C., & Madsbad, S. (1987) · Metabolism · doi:10.1016/0026-0495(87)90153-3 · Cited by 128

APPL1 Potentiates Insulin Sensitivity by Facilitating the Binding of IRS1/2 to the Insulin Receptor

Ryu, J., Galan-Davila, A. K., Xin, X., Dong, F., Abdul-Ghani, M. A., Zhou, L., Wang, C., Li, C., Holmes, B. M., Sloane, L. B., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.006 · Cited by 128

Enhancing Central Nervous System Endogenous GLP-1 Receptor Pathways for Intervention in Alzheimers Disease

Perry, T., & Greig, N. (2005) · Current Alzheimer Research · doi:10.2174/1567205054367892 · Cited by 127

The PI3K-PKB/Akt PathwayPreprint

Hemmings, B. A., & Restuccia, D. F. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a026609 · Cited by 126

Ferroptosis Mediated by Lipid Reactive Oxygen Species: A Possible Causal Link of Neuroinflammation to Neurological Disorders

Cheng, Y., Song, Y., Chen, H., Li, Q., Gao, Y. Z., Lu, G., & Luo, C. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5005136 · Cited by 124

Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans.

Nissen, A., Christensen, M., Knop, F., Vilsbøll, T., Holst, J., & Hartmann, B. (2014) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2014-2547 · Cited by 122

Glucagon‐like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons

Gilman, C. P., Perry, T., Furukawa, K., Grieg, N. H., Egan, J. M., & Mattson, M. P. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02073.x · Cited by 121

Neuroinflammation in mouse models of Alzheimer's disease

Saito, T., & Saido, T. C. (2018) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12475 · Cited by 118

Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer’s Disease

Kosaraju, J., Holsinger, R. M. D., Guo, L., & Tam, K. Y. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0125-7 · Cited by 117

A novel GIP analogue, ZP 4165, enhances glucagon‐like peptide‐1‐induced body weight loss and improves glycaemic control in rodents

Nørregaard, P. K., Deryabina, M. A., Tofteng Shelton, P., Fog, J. U., Daugaard, J. R., Eriksson, P., Larsen, L. F., & Jessen, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13034 · Cited by 116

Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis‐related NLRP3 pathway

Song, S., Guo, R., Mehmood, A., Zhang, L., Yin, B., Yuan, C., Zhang, H., Guo, L., & Li, B. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13791 · Cited by 115

Cytokine Imbalance in Schizophrenia. From Research to Clinic: Potential Implications for Treatment

Reale, M., Costantini, E., & Greig, N. H. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.536257 · Cited by 111

A New Alzheimers Disease Interventive Strategy: GLP-1

Perry, T. R., & Greig, N. H. (2004) · Current Drug Targets · doi:10.2174/1389450043345245 · Cited by 110

Reactive Oxygen Species, Redox Signaling and Neuroinflammation in Alzheimer's Disease: The NF-κB Connection

Kaur, U., Banerjee, P., Bir, A., Sinha, M. S., Biswas, A., & Chakrabarti, S. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150114160543 · Cited by 108

Insulin resistance and exendin-4 treatment for multiple system atrophy

Bassil, F., Canron, M., Vital, A., Bézard, E., Li, Y., Greig, N. H., Gulyani, S., Kapogiannis, D., Fernagut, P., & Meissner, W. G. (2017) · Brain · doi:10.1093/brain/awx044 · Cited by 108

Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease

Cai, H.-Y., Yang, J.-T., Wang, Z.-J., Zhang, J., Yang, W., Wu, M.-N., & Qi, J.-S. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.114 · Cited by 108

Exploring the pathogenesis of IIH: An inflammatory perspective

Sinclair, A. J., Ball, A. K., Burdon, M., Clarke, C. E., Stewart, P. M., Curnow, J., & Rauz, S. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.06.029 · Cited by 107

Lixisenatide rescues spatial memory and synaptic plasticity from amyloid β protein-induced impairments in rats

Cai, H.-Y., Hölscher, C., Yue, X.-H., Zhang, S., Wang, X.-H., Qiao, F., Yang, W., & Qi, J. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.02.022 · Cited by 106

Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice

Li, Y., Bader, M., Tamargo, I. A., Rubovitch, V., Tweedie, D., Pick, C. G., & Greig, N. H. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13169 · Cited by 103

Reduced incidence of Parkinson's disease after dipeptidyl peptidase‐4 inhibitors—A nationwide case‐control study

Svenningsson, P., Wirdefeldt, K., Yin, L., Fang, F., Markaki, I., Efendić, S., & Ludvigsson, J. F. (2016) · Movement Disorders · doi:10.1002/mds.26734 · Cited by 103

New Therapeutic Strategies and Drug Candidates for Neurodegenerative Diseases: p53 and TNF‐α Inhibitors, and GLP‐1 Receptor Agonists

Greig, N. H., Mattson, M. P., Perry, T., Chan, S. L., Giordano, T., Sambamurti, K., Rogers, J. T., Ovadia, H., & Lahiri, D. K. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.018 · Cited by 99

Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease

Athauda, D. S., & Foltynie, T. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.023 · Cited by 97

Exendin-4 attenuates neuronal death via GLP-1R/PI3K/Akt pathway in early brain injury after subarachnoid hemorrhage in rats

Xie, Z., Enkhjargal, B., Wu, L., Zhou, K., Sun, C., Hu, X., Gospodarev, V. V., Tang, J., You, C., & Zhang, J. H. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.040 · Cited by 97

Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice

Rachmany, L., Tweedie, D., Li, Y., Rubovitch, V., Holloway, H. W., Miller, J. P., Hoffer, B. J., Greig, N. H., & Pick, C. G. (2012) · AGE · doi:10.1007/s11357-012-9464-0 · Cited by 95

Chronic oral administration of adipoRon reverses cognitive impairments and ameliorates neuropathology in an Alzheimer’s disease mouse model

Ng, R. C.-L., Jian, M., Ma, O. K.-F., Bunting, M., Kwan, J., Zhou, G.-J., Krishnamoorthi, S., Iyaswamy, A., Chan, P., Li, M., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0701-0 · Cited by 95

Liraglutide and its Neuroprotective Properties—Focus on Possible Biochemical Mechanisms in Alzheimer’s Disease and Cerebral Ischemic Events

Wiciński, M., Socha, M. W., Malinowski, B., Wódkiewicz, E., Walczak, M., Górski, K. M., Słupski, M., & Pawlak-Osińska, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051050 · Cited by 94

Glucagon like peptide-1 (GLP-1) likes Alzheimer’s disease

Simsir, I. Y., Soyaltın, U. E., & Çetinkalp, Ş. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.03.002 · Cited by 93

Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK/SIRT1 signaling and NLRP3 inflammasome

Ammar, R. A., Mohamed, A. F., Kamal, M. M., Safar, M. M., & Abdelkader, N. F. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-00956-6 · Cited by 93

The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease

Perry, T., & Greig, N. H. (2002) · Journal of Alzheimer s Disease · doi:10.3233/jad-2002-4605 · Cited by 91

Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice

Tweedie, D., Rachmany, L., Rubovitch, V., Lehrmann, E., Zhang, Y., Becker, K. G., Perez, E., Miller, J. P., Hoffer, B. J., Greig, N. H., et al. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.10.001 · Cited by 91

GLP‐1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice

Jolivalt, C. G., Fineman, M., Deacon, C. F., Carr, R. D., & Calcutt, N. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01431.x · Cited by 87

Insulin resistance and gray matter volume in neurodegenerative disease

Morris, J. K., Vidoni, E. D., Perea, R. D., Rada, R. C., Johnson, D. K., Lyons, K. E., Pahwa, R., Burns, J. M., & Honea, R. A. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.04.006 · Cited by 87

Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide

Candeias, E. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.807 · Cited by 86

Nitric Oxide Signaling in Neurodegeneration and Cell Death

Dawson, T. M., & Dawson, V. L. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.09.003 · Cited by 86

Pericyte morphology and function.

Alarcón-Martínez, L., Yemişçi, M., & Dalkara, T. (2021) · PubMed · doi:10.14670/hh-18-314 · Cited by 85

Glaucoma and neuroinflammation: An overview

Quaranta, L., Bruttini, C., Micheletti, E., Konstas, A. G. P., Michelessi, M., Oddone, F., Katsanos, A., Sbardella, D., Angelis, G. D., & Riva, I. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2021.02.003 · Cited by 84

The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson’s Disease

Zhang, L., Zhang, L., Li, Y., Li, L., Melchiorsen, J. U., ROSENKILDE, M. M., & Hölscher, C. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-191768 · Cited by 80

Impaired brain insulin signalling in Parkinson's disease

Bassil, F., Delamarre, A., Canron, M., Dutheil, N., Vital, A., Martin‐Négrier, M., Bézard, E., Fernagut, P., & Meissner, W. G. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12760 · Cited by 80

Inflammation, insulin signaling and cognitive function in aged APP/PS1 mice

Denver, P., English, A. R., & McClean, P. L. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.03.032 · Cited by 80

What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson’s Disease: A Post Hoc Analysis

Athauda, D. S., Maclagan, K., Budnik, N., Zampedri, L., Hibbert, S., Skene, S. S., Chowdhury, K., Avilés-Olmos, I., Limousin, P. D., & Foltynie, T. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181329 · Cited by 79

Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia

Igoillo‐Esteve, M., Oliveira, A. F., Cosentino, C., Fantuzzi, F., Demarez, C., Toivonen, S., Hu, A., Chintawar, S., Lopes, M., Pachera, N., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.134221 · Cited by 78

Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke

Nizari, S., Basalay, M., Chapman, P., Korte, N., Korsak, A., Christie, I. N., Theparambil, S. M., Davidson, S. M., Reimann, F., Trapp, S., et al. (2021) · Basic Research in Cardiology · doi:10.1007/s00395-021-00873-9 · Cited by 77

Insulin resistance, neuroinflammation, and Alzheimer’s disease

Najem, D., Bamji‐Mirza, M., Chang, N., Liu, Q. Y., & Zhang, W. (2014) · Reviews in the Neurosciences · doi:10.1515/revneuro-2013-0050 · Cited by 76

Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma

Sterling, J., Hua, P., Dunaief, J. L., Cui, Q. N., & VanderBeek, B. L. (2023) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-319232 · Cited by 75

Diabetes Mellitus as a Risk Factor for Parkinson’s Disease: a Molecular Point of View

Biosa, A., Outeiro, T. F., Bubacco, L., & Bisaglia, M. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1025-9 · Cited by 74

Activation of GLP-1 Receptor Enhances Neuronal Base Excision Repair via PI3K-AKT-Induced Expression of Apurinic/Apyrimidinic Endonuclease 1

Yang, J., Chen, W., Chen, Y.-P., Kuo, C.-Y., & Chen, S. (2016) · Theranostics · doi:10.7150/thno.15993 · Cited by 73

Evaluation of liraglutide in the treatment of Alzheimer's disease

Edison, P., Femminella, G. D., Ritchie, C. W., Holmes, C., Walker, Z., Ridha, B. H., Raza, S., Livingston, N. R., Nowell, J., Busza, G., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.057848 · Cited by 73

Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases

Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193

Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation

Wong, C. K., McLean, B. A., Baggio, L. L., Koehler, J. A., Hammoud, R., Rittig, N., Yabut, J. M., Seeley, R. J., Brown, T. J., & Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.11.009 · Cited by 304

The expanding incretin universe: from basic biology to clinical translation

Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial

Vijiaratnam, N., Girges, C., Auld, G., McComish, R., King, A., Skene, S. S., Hibbert, S., Wong, A., Melander, S., Gibson, R., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02808-3 · Cited by 181

Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances

Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165

Role of trigger receptor 2 expressed on myeloid cells in neuroinflammation－neglected multidimensional regulation of microglia

Zhang, X., Chen, X., Zhang, L., Sun, Y., Liang, Y., Li, H., & Zhang, Y. (2023) · Neurochemistry International · doi:10.1016/j.neuint.2023.105639 · Cited by 23

Limonin (LM) and its derivatives: Unveiling the neuroprotective and anti-inflammatory potential of LM and V-A-4 in the management of Alzheimer's disease and Parkinson's disease

Panda, S. P., Kesharwani, A., Singh, M., Kumar, S., Mayank, Mallick, S. P., & Guru, A. (2024) · Fitoterapia · doi:10.1016/j.fitote.2024.106173 · Cited by 17

TREM2 expression on the microglia resolved lead exposure-induced neuroinflammation by promoting anti-inflammatory activities

Su, P., Zhang, J., Wu, J., Chen, H., Luo, W., & Hu, M. (2023) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2023.115058 · Cited by 13

Microglial TREM2 Mitigates Inflammatory Responses and Neuronal Apoptosis in Angiotensin II-Induced Hypertension in Middle-Aged Mice

Xu, X., Du, L., Jiang, J., Yang, M., Wang, Z., Wang, Y., Tang, T., Fu, X., & Hao, J. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.716917 · Cited by 25

Continuous injection of high-dose lipopolysaccharide modulates microglia polarization via TREM2 to alter the status of septic micePreprint

Qiu, Z., Wang, H., Qu, M., Zhu, S., Zhang, H., Liao, Q., & Miao, C. (2022) · Research Square · doi:10.21203/rs.3.rs-2064325/v1